Akitaka Makiyama

4PUBLICATIONS
62CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jan 21, 2026
HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.

Michiko Nagamine, Takao Fujisawa, Naoya Sakamoto

|May 16, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama

|Jul 18, 2024
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.

Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa

|Mar 04, 2023
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.

Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi

Pageof 1

Frequent Collaborators

3 joint publications

Shigenori Kadowaki

3 joint publications

Yoshito Komatsu

3 joint publications

Hiroki Hara

3 joint publications

Eiji Oki